Please use this identifier to cite or link to this item: http://www.arca.fiocruz.br/handle/icict/646
Title: Retrovirus infections in a sample of injecting drug users in Rio de Janeiro City, Brazil: prevalence of HIV-1 subtypes, and co-infection with HTLV-I/II
Authors: Guimarães, Monick Lindenmeyer
Bastos, Francisco Inácio Pinkusfeld Monteiro
Dias, Paulo Roberto Telles Pires
Castro Filho, Bernardo Galvão
Diaz, Ricardo S.
Bongertz, Vera
Morgado, Mariza Gonçalves
Affilliation: Oswaldo Cruz Foundation. Oswaldo Cruz Institute. Department of Immunology. Laboratory of AIDS and Molecular Immunology. Rio de Janeiro, RJ, Brasil.
Department of Health Information, Center for Information on Science and Technology, FIOCRUZ (UNAIDS Collaborative Centre), Rio de Janeiro, Brazil
Center for Drug Abuse Treatment and Research (NEPAD), State University of Rio de Janeiro, Rio de Janeiro, Brazil
Advanced Public Health Laboratory, Gonçalo Moniz Research Center, FIOCRUZ (UNAIDS Collaborative Centre), Bahia, Brazil
Laboratory of Retrovirology, Federal University of São Paulo, São Paulo, Brazil
Oswaldo Cruz Foundation. Oswaldo Cruz Institute. Department of Immunology. Laboratory of AIDS and Molecular Immunology. Rio de Janeiro, RJ, Brasil.
Oswaldo Cruz Foundation. Oswaldo Cruz Institute. Department of Immunology. Laboratory of AIDS and Molecular Immunology. Rio de Janeiro, RJ, Brasil.
Abstract: Background :Retrovirus infections among injecting drug users (IDUs), a core at-risk population for both HIV-1 and HTLV-I/II infections in Brazil, were assessed within an ongoing cooperative research. Objecti e : The study assessed the seroprevalences of HIV-1 and HTLV-I/II infections, as well as the prevalence of HIV-1 subtypes in a sample of IDUs from Rio de Janeiro, Brazil. An attempt to evaluate HIV incidence was carried out using a dual ‘sensitive/less sensitive’ testing strategy. Study design : Cross-sectional evaluation of 175 IDUs. Serostatus for HIV-1 and HTLV-I/II were established by enzyme-linked immunosorbent assays, and confirmed by western blot. The dual testing strategy aimed to estimate HIV-1 incidence rates. Differentiation between HTLV-I and -II was performed by western blot. DNA samples were polymerase chain reaction amplified by a nested protocol, and HIV-1 subtyping was determined by heteroduplex mobility assay. Results : Forty-six and 29 samples were found to be, respectively, positive for HIV-1 and HTLV-I/II, 15 of them co-infected by both viruses. Among HTLV-I/II-infected patients, 75.9% were infected by HTLV-I. Thirty-one HIV samples were identified as B subtype, with seven of them showing the typical ‘Brazilian B’ pattern in the gp120 V3 loop, and ten were identified as F subtype. The use of less sensitive assays for HIV infection wrongly identified a deeply immunocompromised patient as an incident case. Conclusion :Moderately high seroprevalences were found for both HIV-1 and HTLV-I/II infections, HIV-1/HTLV-I co-infections being of special concern. A non-statistically significant higher prevalence of F subtype was observed, when compared with the distribution of F/B subtypes among Brazilian patients from other exposure categories. No recent HIV-1 infections were detected, but a limitation of the ‘sensitive/less-sensitive’ testing strategy was made evident.
Keywords: Injecting drug users
HIV
HTLV
HIV/HTLV co-infection
Sensitive/less sensitive dual testing strategy for HIV infection
Issue Date: 2001
Publisher: Elsevier Science B.V.
Citation: GUIMARÃES, Monick Lindenmeyer et al. Retrovirus infections in a sample of injecting drug users in Rio de Janeiro City, Brazil: prevalence of HIV-1 subtypes, and co-infection with HTLV-I/II. Journal of Clinical Virology, V.21, p.143-151, 2001.
ISSN: 0095-1137
Copyright: open access
Appears in Collections:ICICT - Artigos de Periódicos

Files in This Item:
File Description SizeFormat 
Bastos_Retroviruses infections in a Sample_2001.pdf98.22 kBAdobe PDFThumbnail
View/Open


FacebookTwitterDeliciousLinkedInGoogle BookmarksBibTex Format mendeley Endnote DiggMySpace

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.